Skip to main content

PLEASE NOTE: For everyone’s safety, Fasken recommends anyone on-site at our Canadian offices be familiar with the COVID-19 recommendations in place which may include one or more of the following: social distancing, hand sanitizing, wearing a mask in common areas and proof of full vaccination. These measures apply to lawyers, staff, clients, service providers and other visitors.

Client Work

Angiotech Pharmaceuticals acquires American Medical Instruments for US$785 million

Fasken
Reading Time 1 minute read Subscribe

Overview

Client

Angiotech Pharmaceuticals

On March 23, 2006, Angiotech Pharmaceuticals, Inc. closed the acquisition of American Medical Instruments Holdings, Inc. (AMI) for approximately US$785 million (C$900 million), subject to post-closing adjustments. The transaction represents the largest acquisition by a Canadian company in the medtech sector. Angiotech is a specialty pharmaceutical company that discovers and develops treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury or trauma. AMI is a leading manufacturer of specialty, single-use medical devices. The acquisition was funded by way of a combination of cash on hand and the proceeds from the concurrent closings of a private placement of US$250 million in aggregate principal amount of 7.75 per cent senior subordinated notes due 2014, and a US$425 million senior secured credit facility consisting of a US$350 million term credit facility and a US$75 million revolving credit facility. Hugo Patenaude (tax) and Angela Onesi (banking) of Fasken Martineau advised Angiotech on Québec tax and banking law.

Team

    Subscribe

    Receive email updates from our team

    Subscribe